DE60042598D1 - Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist. - Google Patents

Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.

Info

Publication number
DE60042598D1
DE60042598D1 DE60042598T DE60042598T DE60042598D1 DE 60042598 D1 DE60042598 D1 DE 60042598D1 DE 60042598 T DE60042598 T DE 60042598T DE 60042598 T DE60042598 T DE 60042598T DE 60042598 D1 DE60042598 D1 DE 60042598D1
Authority
DE
Germany
Prior art keywords
fibromyalgia
irritant
medicaments
syndrome
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042598T
Other languages
English (en)
Inventor
David F Horrobin
Cari Loder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Neuroscience Ltd
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Application granted granted Critical
Publication of DE60042598D1 publication Critical patent/DE60042598D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60042598T 1999-10-12 2000-10-12 Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist. Expired - Lifetime DE60042598D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924172A GB2355191A (en) 1999-10-12 1999-10-12 Combination formulations for fatigue, head injury and strokes
PCT/GB2000/003926 WO2001026623A2 (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke

Publications (1)

Publication Number Publication Date
DE60042598D1 true DE60042598D1 (de) 2009-09-03

Family

ID=10862624

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042598T Expired - Lifetime DE60042598D1 (de) 1999-10-12 2000-10-12 Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.

Country Status (15)

Country Link
US (1) US6441038B1 (de)
EP (1) EP1220689B1 (de)
AU (1) AU782656B2 (de)
CA (1) CA2388377C (de)
CZ (1) CZ20021197A3 (de)
DE (1) DE60042598D1 (de)
GB (1) GB2355191A (de)
HR (1) HRP20020309A2 (de)
HU (1) HUP0203470A3 (de)
MX (1) MXPA02003724A (de)
NO (1) NO20021716L (de)
NZ (1) NZ518306A (de)
PL (1) PL354975A1 (de)
SK (1) SK4672002A3 (de)
WO (1) WO2001026623A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030176773A1 (en) * 2002-03-12 2003-09-18 Gendreau Roger Michael Methods of assessing the level of a subjective symptom
EP1485078B1 (de) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran zur Behandlung von Reizdarmsyndrom
EP1499309A4 (de) * 2002-04-24 2008-05-28 Cypress Bioscience Inc Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP2301537A1 (de) * 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
EP1528920B1 (de) * 2002-08-12 2013-07-24 Yuuichi Murayama Hemmung der abnormalen Prionproteinsproliferation mit Leucine, Isoleucine oder Valine
WO2004030633A2 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
JP2006508978A (ja) * 2002-11-19 2006-03-16 イーライ・リリー・アンド・カンパニー デュロキセチンを用いる胃腸障害の処置
BRPI0406749A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
ATE359079T1 (de) * 2003-01-13 2007-05-15 Dynogen Pharmaceuticals Inc Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
KR101185322B1 (ko) 2003-02-14 2012-09-21 피에르 파브르 메디카먼트 약제 제조용 밀나시프란의 (1에스,2알) 거울상이성체의용도
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
ATE365554T1 (de) 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2545584C (en) 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
WO2005070461A2 (en) 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
WO2006017504A1 (en) * 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss
AU2005290980A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of ADHD, CFS, FM and depression
BRPI0517088A (pt) 2004-11-17 2008-09-30 Biomarin Pharm Inc formulação de comprimido estável
JP2008523090A (ja) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2135603B1 (de) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Zusammensetzungen und Verfahren zur Erhöhung der Insulinsensitivität
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
TW200803901A (en) * 2005-11-28 2008-01-16 Orexigen Therapeutics Inc Methods of treating anxiety disorders
AU2006321942A1 (en) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
WO2007088473A2 (en) * 2006-02-03 2007-08-09 Neurocure Ltd Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2063886A2 (de) 2006-09-12 2009-06-03 Adolor Corporation Verwendung von stickstoff-haltigen spiroverbindungen zur steigerung kognitiver funktionen
WO2008042773A2 (en) * 2006-09-29 2008-04-10 Pdxrx, Inc. Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
ES2906582T3 (es) 2007-04-11 2022-04-19 Biomarin Pharm Inc Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida
PT2792662T (pt) 2007-05-01 2016-07-07 Concert Pharmaceuticals Inc Compostos de morfinano
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
EP3090760A1 (de) * 2008-10-30 2016-11-09 Concert Pharmaceuticals, Inc. Kombination von morphinanverbindungen und antidepressivum zur behandlung von pseudobulbärer affektstörung, neurologischen erkrankungen, hartnäckigen und chronischen schmerzen und gehirnverletzungen
EP2496079A4 (de) 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas Neue kristalline formen von (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenylcyclopropancarboxamid
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
WO2012059933A1 (en) 2010-11-03 2012-05-10 Arch Pharmalabs Limited A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts.
AU2012272731A1 (en) * 2011-06-24 2014-01-30 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
RU2493839C1 (ru) * 2012-02-28 2013-09-27 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения синдрома хронической усталости
DK3730132T3 (da) 2012-06-06 2022-08-08 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2020160263A1 (en) * 2019-01-30 2020-08-06 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431670A (en) * 1980-12-19 1984-02-14 Bernardo Heller D-Phenylalanine treatment
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
JPH10508583A (ja) * 1994-10-05 1998-08-25 カリ ロダー Ｌ−フェニルアラニン、チロシン又はトリプトファン、及びでき得ればビタミンｂ▲下１２▼を配合したロフェプラミンを使用する多発性硬化症及びその他の脱髄性状態の治療
GB2297868B (en) 1995-02-07 1999-04-28 Nokia Mobile Phones Ltd A shielding device
JP3128609B2 (ja) 1996-02-01 2001-01-29 株式会社小糸製作所 車輌用灯具の照射方向制御装置
DK0942751T3 (da) * 1996-07-05 2002-12-02 Wwk Trust Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter
US5765240A (en) * 1996-07-31 1998-06-16 L&P Property Management Co. Spring bedding product collapsible in the transverse direction, and method of making it
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment

Also Published As

Publication number Publication date
AU782656B2 (en) 2005-08-18
PL354975A1 (en) 2004-03-22
HUP0203470A2 (hu) 2003-02-28
US6441038B1 (en) 2002-08-27
AU7932800A (en) 2001-04-23
EP1220689A2 (de) 2002-07-10
NO20021716D0 (no) 2002-04-11
NZ518306A (en) 2004-04-30
MXPA02003724A (es) 2003-10-14
HUP0203470A3 (en) 2005-10-28
SK4672002A3 (en) 2002-09-10
HRP20020309A2 (en) 2004-02-29
NO20021716L (no) 2002-06-10
CA2388377A1 (en) 2001-04-19
EP1220689B1 (de) 2009-07-22
CZ20021197A3 (cs) 2002-09-11
GB2355191A (en) 2001-04-18
WO2001026623A3 (en) 2001-06-21
CA2388377C (en) 2011-02-01
GB9924172D0 (en) 1999-12-15
WO2001026623A2 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
DE60109044D1 (de) Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms
DE69916686D1 (de) Gerät zur Behandlung von Atemstillstand im Schlaf
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
PT1339399E (pt) Combinacoes de drogas (e.g., clorpromazina e pentamidina) para o tratamento de desordens neoplasicas
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60115872D1 (de) Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE307607T1 (de) Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern
ATE376994T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE58905201D1 (de) Mittel zur behandlung des parkinson-syndroms.
BR0202519B1 (pt) métodos para tratamento de material de madeira e para tratamento microbicida de material de madeira.
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
ATE298569T1 (de) Virus behandlung
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
DE69327812D1 (de) Arsen-enthaltende arzneimittel zur behandlung des chronischen ermüdungssyndroms
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60011060D1 (de) Virus behandlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition